Search
Cardiff Oncology Inc
CRDFAdd to Watchlist
0.855USD
+0.004+0.52%
Close 07-31 16:00（ET）Quotes delayed by 15 min
58.48MMarket Cap
LossP/E TTM
More Details of Cardiff Oncology Inc Company
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Cardiff Oncology Inc Info
Ticker SymbolCRDF
Company nameCardiff Oncology Inc
IPO dateJul 27, 2004
CEOErlander (Mark)
Number of employees32
Security typeOrdinary Share
Fiscal year-endJul 27
Address11055 Flintkote Ave
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18589527570
Websitehttps://cardiffoncology.com/
Ticker SymbolCRDF
IPO dateJul 27, 2004
CEOErlander (Mark)
Company Executives of Cardiff Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
2.04M
+33.63%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
60.00K
-12.86%
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
59.07K
+58.18%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
20.00K
--
Dr. Tod Smeal, Ph.D.
Dr. Tod Smeal, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Roger Sidhu, M.D.
Dr. Roger Sidhu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
2.04M
+33.63%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
60.00K
-12.86%
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
59.07K
+58.18%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
FAQs
Who are the top five shareholders of Cardiff Oncology Inc?
The top five shareholders of Cardiff Oncology Inc are: Dr. Gary William Pace, Ph.D.
How many institutions hold shares of Cardiff Oncology Inc (CRDF)?
As of 2026Q1, 239 institutions hold shares of Cardiff Oncology Inc, with a combined market value of approximately 24.09M, accounting for 35.32% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -10611167.00.